NEJM March 2026: Volume 394, Issue 10 – Latest Research

The March 5, 2026 issue of The New England Journal of Medicine features a landmark publication detailing promising results in the treatment of Dravet syndrome, a rare and severe form of epilepsy that begins in infancy. For the first time, data suggest the potential for a disease-modifying therapy, moving beyond simply managing symptoms to addressing the underlying genetic cause. This development offers a glimmer of hope for children and adolescents living with this devastating condition and their families.

Understanding Dravet Syndrome

Dravet syndrome is a genetic neurodevelopmental disorder caused by mutations in the SCN1A gene. This gene provides instructions for making a protein channel that helps regulate the activity of neurons. Mutations in SCN1A disrupt this function, leading to frequent and prolonged seizures, often triggered by fever and developmental delays. Typically, seizures begin in the first year of life, and children with Dravet syndrome experience a plateauing of neurodevelopment around the age of two, falling further behind their peers in achieving developmental milestones. Currently, treatment focuses on managing seizures with anti-seizure medications (ASMs), but these often provide incomplete control and can have significant side effects. There are currently no approved therapies that directly address the root cause of the disease.

Zorevunersen: Targeting the Genetic Root

The publication in NEJM details the results of Phase 1/2a studies and ongoing open-label extension (OLE) studies of an investigational medicine called zorevunersen, developed by Stoke Therapeutics, and Biogen. Zorevunersen is an RNA-targeted therapeutic designed to restore the production of the functional SCN1A protein. Essentially, it aims to “re-write” the genetic code to compensate for the faulty gene. The study involved children and adolescents with Dravet syndrome who were already receiving standard of care ASMs.

The data presented show substantial and durable reductions in seizure frequency, as well as improvements in cognitive and behavioral measures. These positive effects were observed both during the initial treatment period and continued for up to three additional years in the OLE studies. This suggests that zorevunersen may not only suppress seizures but similarly potentially improve long-term neurodevelopmental outcomes.

Study Details and Limitations

The studies included two completed Phase 1/2a trials and an ongoing open-label extension. While the results are encouraging, it’s crucial to understand the limitations. Phase 1/2a trials are designed primarily to assess safety and preliminary efficacy, not to definitively prove a drug’s effectiveness. The open-label extension, while providing longer-term data, lacks the rigor of a randomized, controlled trial because all participants receive the treatment. This means that improvements observed could be due to factors other than the drug itself, such as natural fluctuations in the disease or improvements in supportive care. Further research, specifically larger, placebo-controlled Phase 3 trials, is needed to confirm these findings and establish the true benefit of zorevunersen.

What Does “Disease Modification” Mean?

The term “disease modification” is significant because it implies that the therapy is altering the underlying course of the disease, rather than simply treating the symptoms. In the context of Dravet syndrome, this means potentially preventing or slowing down the neurodevelopmental decline that typically occurs. However, it’s important to note that the long-term effects of zorevunersen on neurodevelopment are still being investigated. The ongoing Phase 3 EMPEROR study will be critical in determining whether these early improvements translate into sustained benefits.

The Broader Context of Dravet Syndrome Research

Dravet syndrome affects an estimated 1 in 15,000 to 20,000 live births. The Dravet Foundation provides comprehensive information about the condition and supports research efforts. The development of zorevunersen represents a significant shift in the approach to treating Dravet syndrome, moving away from purely symptomatic management towards targeted therapies that address the genetic cause. Other investigational therapies targeting different aspects of the disease are also in development, offering hope for a wider range of treatment options in the future. The National Institutes of Health’s ClinicalTrials.gov website lists ongoing studies related to Dravet syndrome.

What Comes Next: The Path to Potential Approval

The publication of these data in NEJM is a major step forward, but it is not the finish of the story. The ongoing Phase 3 EMPEROR study is crucial. This larger, randomized, placebo-controlled trial will provide more definitive evidence of zorevunersen’s efficacy and safety. If the results of the Phase 3 trial are positive, Stoke Therapeutics and Biogen plan to seek regulatory approval from agencies such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe. The regulatory review process will involve a thorough evaluation of the data to determine whether the benefits of zorevunersen outweigh the risks. If approved, zorevunersen could become the first disease-modifying therapy for Dravet syndrome, offering a new hope for individuals and families affected by this challenging condition.